A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy

Annals of Hematology

Volumn 95, Issue 7, 2016, Pages 1137-1143

  Awan, Farrukh T ^a   Jones, Jeffrey A ^a   Maddocks, Kami ^a   Poi, Ming ^a   Grever, Michael R ^a   Johnson, Amy ^a   Byrd, John C ^a   Andritsos, Leslie A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b Starling Loving Hall ^*  (United States)

Author keywords

Chronic lymphocytic leukemia; Flavopiridol

Indexed keywords

ANTINEOPLASTIC AGENT; FLAVONOID; FLAVOPIRIDOL; PIPERIDINE DERIVATIVE;

AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PROCEDURES; TREATMENT OUTCOME; TRENDS;

AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FLAVONOIDS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PIPERIDINES; TREATMENT OUTCOME;

EID: 84964413013     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-016-2683-1     Document Type: Article

References (25)

1. Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–74
2. Awan FT, Hillmen P, Hellmann A et al (2014) A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol 167:466–77
3. Robak T, Dmoszynska A, Solal-Celigny P et al (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756–65
4. Awan FT, Byrd JC (2014) New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. Clin Cancer Res 20:5869–74
5. Schweighofer CD, Ritgen M, Eichhorst BF et al (2009) Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 144:95–8
6. Shanafelt TD, Ramsay AG, Zent CS et al (2013) Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood 121:4137–41
7. Del Poeta G, Del Principe MI, Buccisano F et al (2008) Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 112:119–28
8. van Oers MH, Kuliczkowski K, Smolej L et al (2015) Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 16(13):1370–9
9. Blum KA, Ruppert AS, Woyach JA et al (2011) Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia 25:1444–51
10. Byrd JC, Lin TS, Dalton JT et al (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399–404
11. Byrd JC, Peterson BL, Gabrilove J et al (2005) Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 11:4176–81
12. Phelps MA, Rozewski DM, Johnston JS et al (2008) Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci 868:110–5
13. Jones JA, Rupert AS, Poi M et al (2014) Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin’s lymphoma. Am J Hematol 89:19–24
14. Hofmeister CC, Poi M, Bowers MA et al (2014) A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemother Pharmacol 73:249–57
15. Ramaswamy B, Phelps MA, Baiocchi R et al (2012) A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Invest New Drugs 30:629–38
16. Fischer K, Cramer P, Busch R et al (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29:3559–66
17. Wierda W, O’Brien S, Wen S et al (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070–8
18. Lin TS, Ruppert AS, Johnson AJ et al (2009) Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27:6012–8
19. Stephens DM, Ruppert AS, Blum K et al (2012) Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica 97:423–7
20. Abrisqueta P, Villamor N, Terol MJ et al (2013) Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood 122:3951–9
21. Byrd JC, Furman RR, Coutre SE et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32–42
22. Brown JR, Byrd JC, Coutre SE et al (2014) Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 123:3390–7
23. Roberts AW, Davids MS, Pagel JM et al (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374:311–22
24. Byrd JC, Harrington B, O’Brien S et al (2016) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 374:323–32
25. Furman RR, Sharman JP, Coutre SE et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997–1007